Synapedia Research & Intelligence
An editorial hub for evidence-oriented guides, emerging-substance context, warning signals, and durable knowledge — without hype, dosing, or procurement guidance.
Opioid withdrawal explained medically: timeline, symptoms, relapse and overdose risk, red flags, evidence, and harm reduction.
Editorial selection
Current orientation and essential reading from the existing canonical knowledge system.
Kratom withdrawal explained: opioid-like mechanisms, timeline, symptoms, evidence gaps, red flags, and harm reduction.
Related substances:Kratom · Morphine · Tramadol
Phenibut withdrawal explained: GABA-B adaptation, insomnia, agitation, delirium risk, red flags, evidence limits, and harm reduction.
Benzodiazepine withdrawal explained: GABA-A adaptation, rebound anxiety, seizure risk, medical red flags, evidence, and harm reduction.
Stimulant withdrawal explained: crash, dysphoria, craving, sleep debt, psychosis risk, red flags, evidence, and harm reduction.
Cannabis withdrawal explained: sleep, appetite, irritability, anxiety, relapse triggers, mental-health red flags, and harm reduction.
Monitoring without ranking
Observation points from existing substance profiles and official source records. This is not a popularity list.
A signal indicates observability, not safety, quality, or a recommendation. Limited evidence remains limited even when attention increases.
Stimulants
NEP (N-ethylpentedrone, N-ethylnorpentedrone) is a synthetic cathinone research chemical with stimulant monoaminergic effects. EUDA monitors NEP as a new psychoactive substance, and the 2026 European Drug…
Early-warning context
Official monitoring; limited substance-specific human data
Profile and sourcesStimulants
3-CMC (3-chloromethcathinone, also called clophedrone) is a synthetic cathinone research chemical with stimulant, monoaminergic effects. EUDA/EMCDDA and WHO assessments identify 3-CMC as a new psychoactive…
Risk assessment available
Official assessment plus scientific literature
Profile and sourcesBenzodiazepines
Bromazolam is an unapproved designer benzodiazepine in the triazolobenzodiazepine group. WHO reviews, public-health alerts, DEA documents and forensic case series describe increasing detections, mislabelled…
Public-health alert in source profile
Official alerts plus scientific literature
Profile and sourcesOpioids
7-Hydroxymitragynine (7-OH) is not just stronger kratom. It is a potent opioid-receptor-active kratom alkaloid now appearing in high-concentration consumer products, with reported dependence and opioid-like…
Public-health alert in source profile
Official alerts plus scientific literature
Profile and sourcesSource-based notices
Compact context from existing official alerts and scientific risk assessments. Visual urgency follows the source type.
7-Hydroxymitragynine (7-OH) is not just stronger kratom. It is a potent opioid-receptor-active kratom alkaloid now appearing in high-concentration consumer products, with reported dependence and opioid-like withdrawal. Synapedia…
Bromazolam is an unapproved designer benzodiazepine in the triazolobenzodiazepine group. WHO reviews, public-health alerts, DEA documents and forensic case series describe increasing detections, mislabelled tablets and deaths,…
3-CMC (3-chloromethcathinone, also called clophedrone) is a synthetic cathinone research chemical with stimulant, monoaminergic effects. EUDA/EMCDDA and WHO assessments identify 3-CMC as a new psychoactive substance associated…
Evidence in context
Research and safety questions reduced to their essentials — including the evidence frame and limits of each conclusion.
Evidence note 01
Evidence note 02
Evidence note 03
Durable knowledge
The English hub currently exposes only topic areas with complete, meaningful English guides.
Guided research
Three existing, complete guides per path — a deliberate starting point instead of an endless index.
Evidence-oriented context for withdrawal patterns that can require medical assessment.
Sleep, mood, craving, and post-acute uncertainty across different substance classes.
Sources are separated by type and strength. Official notices, scientific literature, pharmacological inference, and community signals are not interchangeable forms of evidence. Where evidence is weak, that uncertainty remains visible.
Content supports education and harm reduction. It is not consumption, dosing, diagnosis, taper, or treatment advice.
